Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation
Preventive treatment of focal and segmental glomerusclerosis (FSGS) allograft recurrence in high risk recipients having a prior history of graft loss caused by FSGS recurrence is still a challenging question. We retrospectively identified four patients who underwent a second renal transplantation because of recurrent FSGS and who received Rituximab therapy as a prophylactic treatment. Loss of their first allograft was directly related to an early (<3 months) recurrence of FSGS that was either resistant to plasmapheresis therapy in two cases or had escaped to this therapeutic management in the two others. After the second renal transplantation, all patients were free of FSGS recurrence during follow‐ups that were between 12 and 54 months long. These preliminary results demonstrate for the first time that Rituximab therapy may constitute an attractive prophylactic option for patients being considered for a second renal transplantation because of recurrent FSGS in their first graft.
Document Type: Research Article
Affiliations: 1: Service de Néphrologie et Transplantation, Hôpital Henri Mondor, AP-HP, Institut Francilien de recherche en Néphrologie et Transplantation (IFRNT), Paris Est Université Créteil, France 2: Service de Néphrologie, Dialyse et Transplantation d’Organe, CHU Rangueil, Toulouse and INSERM U563, IFR –BMT, CHU Purpan, Université Paul Sabatier, Toulouse, France
Publication date: May 1, 2012